Abstracts

HBV Eradication: Similarities to and Differences From HIV

Background: Chronic hepatitis B virus (HBV) infection is a major public health concern affecting over 500 million people worldwide. HBV is a partially double stranded DNA virus that preferentially infects hepatocytes and causes acute hepatitis. While this acute hepatitis resolves in most patients, a subset of patients progress to chronic hepatitis with development of liver…

Humoral Immunity and the Innate Response to HCV

Background: Hepatitis C virus (HCV) infection is a blood born disease with global distribution that affects almost 3% of the world’s population and 25% of those with HIV in the United States. In the United States and many other countries, HCV remains the leading cause of liver failure requiring transplantation and of hepatocellular carcinoma. Continuing…

Interferon Alfa-Free Treatment of HCV

Background: Hepatitis C therapy is living its revolution. Several new anti-hepatitis C virus (HCV) drugs have reached the market and many others, including direct-acting antivirals (DAAs) and host-targeted agents (HTAs), are at the late clinical developmental stage. Several all-oral, interferon-free drug combination strategies are being developed, including nucleotide-based strategies, nucleoside-free strategies based on 3 DAAs…

ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage

Background: HCV NS3/4A protease inhibitors (PIs) are proven therapeutic agents used in treating chronic HCV infection. First generation PIs (boceprevir or telaprevir), when combined with pegylated interferon and ribavirin (P/R), improve the cure rate in patients harboring HCV genotype (GT) 1 infections. Their usage, however, is limited by the emergence of drug resistant variants during…

ABT-530 an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Barrier to Resistance

Background: NS5A plays a critical role in HCV replication. Results from clinical studies with first generation NS5A inhibitors have validated NS5A as a drug target for direct-acting antiviral (DAA) therapy. We report here the virological characterization of a next generation HCV NS5A inhibitor, ABT-530, which has a more favorable preclinical profile than earlier generation NS5A…

Longitudinal Analysis of RAVs by PrimerID 454-sequencing in the boceprevir P-05063 Study

Background: Although resistance associated amino acid variants (RAVs) declined to below detectable levels by Sanger sequencing methodology in the majority of patients enrolled in the long-term follow-up study P05063, ~30% of these patients had viruses with RAVs detected by population sequencing >2 years after cessation of boceprevir dosing. In order to further investigate the persistence…

Ritonavir-Boosted Atazanavir Lopinavir & Darunavir Increase HCV NS5A Inhibitor MK-8742 Levels

Background: MK-8742, a potent, once-daily inhibitor of the hepatitis C virus (HCV) NS5A, is being developed for the treatment of chronic HCV infection in mono- and HCV/human immunodeficiency virus (HIV)-coinfected patients. The aim of this study was to assess the potential two-way pharmacokinetic (PK) interaction and tolerability of MK-8742 when coadministered with ritonavir (RTV)-boosted HIV…

Use of Dried Blood Spots for Measuring Intracellular Ribavirin-Triphosphate

Background: Ribavirin (RBV), a nucleoside analog, undergoes intracellular phosphorylation to a mono-(MP), di-(DP), and triphosphate (TP). RBV-TP accumulates in red blood cells (RBC) leading to ATP depletion, membrane oxidative damage, and ultimately hemolytic anemia. Therefore, measuring RBV-TP in RBC is of interest for pharmacokinetic/dynamic analyses. We describe the development and validation of a method to…

Hepatitis C antigen testing: a reliable alternative for diagnosing acute HCV infection

Background: In recent years there have been multiple epidemics of Hepatitis C (HCV) co-infection in HIV-infected populations. The early identification of acute HCV infection can have important implications for both treatment and partner notification to reduce onwards transmission. Acute HCV infection is diagnosed using HCV RNA testing methods which are more sensitive and specific then…